Anzeige
Mehr »
Login
Samstag, 23.11.2024 Börsentäglich über 12.000 News von 677 internationalen Medien
Microsofts, Googles und Amazons nukleares Wettrennen macht diese Uranaktie zu einem Muss!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: 931150 | ISIN: NO0010000045 | Ticker-Symbol: PHS
Tradegate
22.11.24
14:52 Uhr
4,240 Euro
+0,050
+1,19 %
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
PHOTOCURE ASA Chart 1 Jahr
5-Tage-Chart
PHOTOCURE ASA 5-Tage-Chart
RealtimeGeldBriefZeit
4,1254,28013:04
4,1704,21022.11.

Aktuelle News zur PHOTOCURE Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
13.11.Photocure ASA reports Q3 results1
PHOTOCURE Aktie jetzt für 0€ handeln
13.11.PHOTOCURE ASA Q3 Loss Declines3
13.11.Photocure ASA: Results for the third quarter of 2024258OSLO, Norway, Nov. 13, 2024 /PRNewswire/ -- Photocure ASA (OSE: PHO) today reported Hexvix®/Cysview® revenues of NOK 120.1 million in the third quarter of 2024 (Q3 2023: NOK 107.3 million)...
► Artikel lesen
06.11.Photocure ASA: Invitation to presentation of third quarter 2024 financial results-
05.11.Photocure ASA: Photocure Partner Asieris announces Marketing Approval by the National Medical Products Administration for Hexvix in China-
05.11.Photocure Partner Asieris announces Marketing Approval by the National Medical Products Administration for Hexvix in China1
30.09.Photocure ASA: Photocure Partner Asieris Unveils Cevira Phase III Subgroup Analysis by Age Groups at the 2024 CSCO Annual Meeting4
30.09.Photocure Partner Asieris Unveils Cevira (APL-1702) Phase III Subgroup Analysis by Age Groups at the 2024 CSCO Annual Meeting426OSLO, Norway, Sept. 30, 2024 /PRNewswire/ -- Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces that its partner Asieris Pharmaceuticals (SSE: 688176) communicated that international...
► Artikel lesen
27.09.Photocure establishes Named Patient Program to provide access to Hexvix in South Africa330OSLO, Norway, Sept. 27, 2024 /PRNewswire/ -- Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces that it entered into an agreement with Equity Pharmaceuticals PTY Limited, part...
► Artikel lesen
27.09.Photocure ASA: Photocure establishes Named Patient Program to provide access to Hexvix in South Africa2
17.09.Cevira (APL-1702): Photocure Partner Asieris Unveils Efficacy Data of Non-Surgical Treatment of Cervical HSIL at the 2024 PDT&PD Conference662OSLO, Norway, Sept. 17, 2024 /PRNewswire/ -- Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces that its partner Asieris Pharmaceuticals (SSE: 688176) has communicated today...
► Artikel lesen
17.09.Photocure ASA: Cevira: Photocure Partner Asieris Unveils Efficacy Data of Non-Surgical Treatment of Cervical HSIL at the 2024 PDT&PD Conference4
16.09.Photocure ASA: Notification of major shareholding9
08.08.Photocure ASA reports Q2 results3
07.08.PHOTOCURE ASA Bottom Line Rises In Q2-
07.08.Photocure ASA: Results for the second quarter of 2024245OSLO, Norway, Aug. 7, 2024 /PRNewswire/ -- Photocure ASA (OSE: PHO), The Bladder Cancer Company, today reported Hexvix®/Cysview® revenues of NOK 122.4 million in the second quarter of 2024...
► Artikel lesen
31.07.Photocure ASA: Invitation to presentation of second quarter and first half year 2024 financial results1
15.07.Photocure and Richard Wolf Enter into Agreement to Develop a High-Definition Flexible Blue Light Cystoscope for Global Commercialization535OSLO, Norway, July 15, 2024 /PRNewswire/ -- Photocure ASA (OSE: PHO), the Bladder Cancer Company, today announces that it has entered into a strategic agreement with Richard Wolf GmbH to...
► Artikel lesen
15.07.Photocure ASA: Photocure and Richard Wolf Enter into Agreement to Develop a High-Definition Flexible Blue Light Cystoscope for Global Commercialization1
04.06.Photocure Announces Mobile BLC Tower Initiative to Expand Access to Cysview in the U.S.401OSLO, Norway, June 4, 2024 /PRNewswire/ -- Photocure ASA (OSE: PHO), the Bladder Cancer Company, today announces that it has commenced activities to support a new initiative enabling U.S....
► Artikel lesen
Seite:  Weiter >>
34 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1